Borage oil GLA for atopic dermatitis: where the evidence collapsed

← Back to articles

Borage seed oil is one of the richest natural sources of gamma-linolenic acid (GLA), and for roughly two decades it was a leading complementary therapy for eczema. Then the largest randomized trials and a Cochrane systematic review converged on a less flattering conclusion: GLA from borage or evening primrose oil does not meaningfully improve atopic dermatitis. It is a clean case study in how a tidy biological mechanism can outrun the trial data, and how small early studies can manufacture a market that later, better studies fail to support.

The mechanism that looked promising

Borage oil contains a high percentage of GLA, an omega-6 fatty acid that sits downstream of the delta-6-desaturase enzyme. Researchers in the 1980s noted that some people with atopic dermatitis appeared to have reduced delta-6-desaturase activity, which led to a plausible hypothesis: supply GLA directly, bypass the sluggish enzyme, restore the skin's fatty-acid and ceramide profile, dampen inflammatory eicosanoid signaling, and improve the skin barrier. Early, mostly small trials — many tied to manufacturers — reported eczema improvements, and that built the commercial category for both borage oil and the higher-profile evening primrose oil.

What the larger trials showed

As better-powered, independent trials arrived, the signal faded. The most-cited is a 2003 BMJ trial by Takwale and colleagues: a randomized, double-blind, placebo-controlled study of 140 evaluable adults and children with atopic eczema, given borage oil delivering 920 mg GLA daily (adults) for 12 weeks. The mean SASSAD severity score actually fell slightly more in the placebo group; the difference of 1.4 points favored placebo and was not statistically significant, and no other outcome separated from placebo [1]. An earlier multicenter European trial by Henz and colleagues randomized 160 adults with stable, moderate atopic eczema to borage oil or placebo for 24 weeks and likewise found no statistically significant overall benefit, with only a questionable subgroup signal [2]. A separate strategy — giving borage-oil GLA to infants at high familial risk to prevent eczema — also failed its primary endpoints, showing at most a non-significant trend in severity and no effect on total IgE [3].

The Cochrane verdict

The question was effectively settled by the 2013 Cochrane review (Bamford and colleagues), which pooled 27 randomized trials with 1,596 participants — 19 of evening primrose oil and 8 of borage oil. It concluded that neither oil produced a clinically meaningful improvement in eczema over placebo; pooled global symptom scores were essentially identical between active treatment and placebo [4]. The reviewers went further than the usual "more research needed" hedge, noting that the confidence intervals were narrow enough to exclude a clinically useful effect, so further trials of these oils for eczema would be hard to justify.

Why the early signal evaporated

The familiar pattern applies. The positive studies tended to be small, were often industry-funded, and sometimes leaned on subgroup analyses or surrogate biomarkers (such as rising blood GLA-metabolite levels) rather than on the symptoms patients care about. Once trials were large, properly blinded, allocation-concealed, and analyzed by intention-to-treat, the apparent benefit dissolved. A correct biological rationale is not the same as a clinically useful drug.

Other proposed uses of GLA

GLA has been studied for rheumatoid arthritis, diabetic neuropathy, and cyclical breast pain, but for none of these is the evidence robust or consistent, and effect sizes are generally small. We are not citing those literatures here because they fall outside this article's scope; the relevant point is that the atopic-dermatitis indication — once the strongest commercial use — did not survive rigorous testing, and the others are not on firmer ground.

Safety

Borage oil is generally well tolerated; the adverse effects seen in trials were mainly mild and gastrointestinal, similar to placebo [4]. The more specific concern is botanical: borage plants contain pyrrolizidine alkaloids, which are hepatotoxic. Reputable manufacturers test for and reduce these to undetectable levels, but product quality varies, so certification matters. Theoretical bleeding-risk interactions with anticoagulants are sometimes raised but are rarely material at supplement doses. Given the absence of demonstrated benefit for eczema, the practical conclusion is simple: standard emollient and topical therapy, not GLA capsules.

Sources

1. Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, Thompson JR, Chapman T, Berth-Jones J. "Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial." BMJ, 2003;327(7428):1385. PMID 14670885. DOI: 10.1136/bmj.327.7428.1385.
2. Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG, Veenhuizen R, Muggli R, Raederstorff D. "Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema." Br J Dermatol, 1999;140(4):685-8. PMID 10233322. DOI: 10.1046/j.1365-2133.1999.02771.x.
3. van Gool CJ, Thijs C, Henquet CJ, van Houwelingen AC, Dagnelie PC, Schrander J, Menheere PP, van den Brandt PA. "Gamma-linolenic acid supplementation for prophylaxis of atopic dermatitis--a randomized controlled trial in infants at high familial risk." Am J Clin Nutr, 2003;77(4):943-51. PMID 12663296. DOI: 10.1093/ajcn/77.4.943.
4. Bamford JTM, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. "Oral evening primrose oil and borage oil for eczema." Cochrane Database Syst Rev, 2013;2013(4):CD004416. PMID 23633319. DOI: 10.1002/14651858.CD004416.pub2.